Established in 2021, RinuaGene Biotechnology Co., Ltd. is committed to the research and development of innovative mRNA therapeutics and vaccines. The company efficiently advances its FIC/BIC product pipeline and robust technological platform with a solid foundation in technical expertise, pharmaceutical industry experience, and managerial capabilities. Driven by innovation, RinuaGene is striving to build formidable international competitiveness.
Preventive vaccines for infectious diseases, virus-related therapeutic vaccines, tumor immunotherapies, and protein replacement therapies.
Optimization of linear mRNA and circular RNA design, efficient targeted delivery, robust CMC, data science, and AI for RNA.
A comprehensive international patent layouts that fully covers the product pipeline and technology platforms, with 74 invention patents and 3 software copyrights filed as of August 2024.
Equipped with full-spectrum mRNA drug development capabilities, with 80% of the workforce engaged in R&D, and over 60% holding master's or doctoral degrees.
RinuaGene is dedicated to establishing a world-leading platform for innovative and efficient RNA therapeutics and vaccine technologies, to provide innovative and high-quality solutions to address critical health challenges in China and around the globe.
Innovation Project of "Revealing the List and Taking the Lead" in Cell Therapy of National Center of Technology Innovation for Biopharmaceuticals.
Jiangsu Province "Entrepreneurship and Innovation" Entrepreneurial Talent.
Jiangsu Province "Entrepreneurship and Innovation" Innovative Talent.
Jiangsu "Potential Unicorn" Enterprise.
Jiangsu Suzhou "Unicorn Cultivation" Enterprise.
Gusu Leading Talent (Regional Key Talent).
Suzhou Industrial Park Jinji Lake Talent.
© 2024 RinuaGene. All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.